Evaluation of Vancomycin Based on Healthcare Infection Control Practices Advisory Committee Guideline in Emam Khomeini Hospital of Urumie
Abstract
Background: The present study was conducted to evaluate the use of vancomycin accordingto the Healthcare Infection Control Practices Advisory Committee guidelines in the ImamKhomeini hospital of Urmia.Methods: This retrospective study was conducted in Urmia Imam Khomeini Hospital(intensive care unit, surgery, internal medicine, and dialysis wards). In the retrospective phase,the demographic and clinical data related to all patients who were treated with vancomycinin April, May, and June 2015 were collected according to a HICPAC-based questionnaire. Thelevel of compliance of vancomycin with the recommendations mentioned was determined.Non-compliance with the instructions was identified as the goal of the next interventions.Results: The results of our study showed that the highest starting doses were among thepatients with pneumonia. We did not measure the serum level of vancomycin in none of thepatients studied. The duration of treatment for patients was 4.45±4.91 days. Also, our resultsshowed that 68.5% of patients had no antibiogram before the treatment.Conclusion: The obtained findings showed that the necessity of an antibiogram and patient’sweight measurement and avoiding the simultaneous use of broad-spectrum antibioticsand measuring the serum level of vancomycin in order to promote patients’ treatmentand promote the use of broad-spectrum antibiotics Vancomycin should be taken intoconsideration.
[1] Laing RO, Hogerzeil HV, Ross-Degnan D. Ten recommendations to improve use of medicines in developing countries. Health Policy Plan. 2001; 16(1):13-20. [DOI:10.1093/heapol/16.1.13]
[2] Rowe AK, de Savigny D, Lanata CF, Victora CG. How can we achieve and maintain high-quality performance of health workers in lowresource settings? Lancet. 2005; 366(9490):1026-35. [DOI:10.1016/S0140-6736(05)67028-6]
[3] Benkó R, Bácskai T, Hajdú E, Matuz M, Soós G. [Analysis of antibiotic consumption of five different clinical departments, especially considering the features of hematology departments (Hu)]. Acta Pharm Hung. 2002; 72(4):245-51. [PMID]
[4] Palizvan MR, Rafiei M, Khazaee MR. [Assesment and comparison of drug use among medical and non-medical staff members in Markazi Province, Iran (Persian)]. J Arak Univ Med Sci. 2012; 15(2):27-34. http://jams.arakmu.ac.ir/article-1-1134-en.html
[5] Gupta A, Biyani M, Khaira A. Vancomycin nephrotoxicity: Myths and facts. Neth J Med. 2011; 69(9):379-83. [PMID]
[6] Bruniera FR, Ferreira FM, Saviolli LRM, Bacci MR, Feder D, da Luz Gonçalves Pedreira M, et al. The use of vancomycin with its therapeutic and adverse effects: A review. Eur Rev Med Pharmacol Sci. 2015; 19(4):694-700. [PMID]
[7] Hicks RW, Hernandez J. Perioperative pharmacology: A focus on vancomycin. AORN J. 2011; 93(5):593-6; quiz 597-9. [DOI:10.1016/j. aorn.2010.09.031] [PMID]
[8] Plan O, Cambonie G, Barbotte E, Meyer P, Devine C, Milesi C, et al. Continuous-infusion vancomycin therapy for preterm neonates with suspected or documented Gram-positive infections: A new dosage schedule. Arch Dis Child Fetal Neonatal Ed. 2008; 93(6):F418-21. [DOI:10.1136/adc.2007.128280] [PMID]
[9] Badran EF, Shamayleh A, Irshaid YM. Pharmacokinetics of vancomycin in neonates admitted to the neonatology unit at the Jordan University Hospital. Int J Clin Pharmacol Ther. 2011; 49(4):252-7.
[DOI:10.5414/CP201456] [PMID]
[10] Alfandari S, Levent T, Descamps D, Hendricx S, Bonenfant C, Taines V, et al. Evaluation of glycopeptide use in nine French hospitals. Med Mal Infect. 2010; 40(4):232-7. [DOI:10.1016/j.med�-mal.2009.10.019] [PMID]
[11] Wright SW, Wrenn KD. Appropriateness of vancomycin use in the emergency department. Ann Emerg Med. 1998; 32(5):531-6.
[DOI:10.1016/S0196-0644(98)70030-7] [PMID]
[12] Khera M, Pathengay A, Jindal A, Jalali S, Mathai A, Pappuru RR, et al. Vancomycin-resistant Gram-positive bacterial endophthalmitis: Epidemiology, treatment options, and outcomes. J Ophthalmic Inflamm Infect. 2013; 3(1):46. [DOI:10.1186/1869-5760-3-46] [PMID] [PMCID]
[2] Rowe AK, de Savigny D, Lanata CF, Victora CG. How can we achieve and maintain high-quality performance of health workers in lowresource settings? Lancet. 2005; 366(9490):1026-35. [DOI:10.1016/S0140-6736(05)67028-6]
[3] Benkó R, Bácskai T, Hajdú E, Matuz M, Soós G. [Analysis of antibiotic consumption of five different clinical departments, especially considering the features of hematology departments (Hu)]. Acta Pharm Hung. 2002; 72(4):245-51. [PMID]
[4] Palizvan MR, Rafiei M, Khazaee MR. [Assesment and comparison of drug use among medical and non-medical staff members in Markazi Province, Iran (Persian)]. J Arak Univ Med Sci. 2012; 15(2):27-34. http://jams.arakmu.ac.ir/article-1-1134-en.html
[5] Gupta A, Biyani M, Khaira A. Vancomycin nephrotoxicity: Myths and facts. Neth J Med. 2011; 69(9):379-83. [PMID]
[6] Bruniera FR, Ferreira FM, Saviolli LRM, Bacci MR, Feder D, da Luz Gonçalves Pedreira M, et al. The use of vancomycin with its therapeutic and adverse effects: A review. Eur Rev Med Pharmacol Sci. 2015; 19(4):694-700. [PMID]
[7] Hicks RW, Hernandez J. Perioperative pharmacology: A focus on vancomycin. AORN J. 2011; 93(5):593-6; quiz 597-9. [DOI:10.1016/j. aorn.2010.09.031] [PMID]
[8] Plan O, Cambonie G, Barbotte E, Meyer P, Devine C, Milesi C, et al. Continuous-infusion vancomycin therapy for preterm neonates with suspected or documented Gram-positive infections: A new dosage schedule. Arch Dis Child Fetal Neonatal Ed. 2008; 93(6):F418-21. [DOI:10.1136/adc.2007.128280] [PMID]
[9] Badran EF, Shamayleh A, Irshaid YM. Pharmacokinetics of vancomycin in neonates admitted to the neonatology unit at the Jordan University Hospital. Int J Clin Pharmacol Ther. 2011; 49(4):252-7.
[DOI:10.5414/CP201456] [PMID]
[10] Alfandari S, Levent T, Descamps D, Hendricx S, Bonenfant C, Taines V, et al. Evaluation of glycopeptide use in nine French hospitals. Med Mal Infect. 2010; 40(4):232-7. [DOI:10.1016/j.med�-mal.2009.10.019] [PMID]
[11] Wright SW, Wrenn KD. Appropriateness of vancomycin use in the emergency department. Ann Emerg Med. 1998; 32(5):531-6.
[DOI:10.1016/S0196-0644(98)70030-7] [PMID]
[12] Khera M, Pathengay A, Jindal A, Jalali S, Mathai A, Pappuru RR, et al. Vancomycin-resistant Gram-positive bacterial endophthalmitis: Epidemiology, treatment options, and outcomes. J Ophthalmic Inflamm Infect. 2013; 3(1):46. [DOI:10.1186/1869-5760-3-46] [PMID] [PMCID]
| Files | ||
| Issue | Vol 4 No 3/4 (2018) | |
| Section | Original Article(s) | |
| Keywords | ||
| Vancomycin Infection Guidelines Antimicrobial use | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Shiva A, Azemoodeh M. Evaluation of Vancomycin Based on Healthcare Infection Control Practices Advisory Committee Guideline in Emam Khomeini Hospital of Urumie. JPPM. 2018;4(3/4):53-57.
